TITLE:
Study Evaluating ReFacto in Hemophilia A

CONDITION:
Hemophilia A

INTERVENTION:
BDDrFVII

SUMMARY:

      To identify the causative mutations in previously untreated patients with hemophilia A
      enrolled in the ReFacto clinical safety and efficacy study CTN 93-R833-0XX/C9741-28, using
      two established hemophilia mutation testing laboratories (one in Europe and one in North
      America).
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: All
Age: N/A to N/A
Criteria:

        Inclusion Criteria:

          -  Patients who were or are enrolled in Study CTN 93-R833-0XX/C9741-28, and have been
             treated with ReFacto during this study are eligible for participation.

          -  The patient (or legal guardian) must be willing to give written informed consent
             before any study-related procedures are performed.

          -  A blood sample will be collected from each patient for the purpose of this study and
             will be analyzed at one or both of the designated central laboratories.

        Exclusion Criteria:

          -  Any condition which, in the investigator's opinion, places the patient at undue risk.
      
